U.S. demand for the drugs, known as GLP-1 agonists, exceeded supply in 2023, and some analysts predict the market could surpass $150 billion a year within a decade.
Primary care doctors, who typically have little training in obesity, have been increasingly cast as gatekeepers and are dealing with heightened demand from patients, including many who are overweight but may benefit from other treatments.
[
add
]
[
|
|
...
]